Cerebellar metastasis of gastrointestinal stromal tumor: A case report and review of the literature

Badri, Mohamed; Chabaane, Mohamed; Gader, Ghassen; Bahri, K.; Zammel, I.

doi:10.1016/j.ijscr.2017.12.009

Cited by 8 publications

(4 citation statements)

References 9 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The estimated PFS was 5 months (Figure 2B). Regarding the 17 undefined irradiated lesions in 17 patients, 13 patients were from 13 case reports [16,18,19,24,25,27,33,36,[38][39][40]42,44], and the other 4 patients were from one case series [45]. The four patients with rectal GISTs treated by adjuvant radiotherapy without TKIs after surgery were all alive and had no recurrence during a follow-up of 21-75 months.…”

Section: Patient Response To Radiation and Follow-upmentioning

confidence: 99%

Radiotherapy in the Management of Gastrointestinal Stromal Tumors: A Systematic Review

Zhang

Jiang

et al. 2022

Cancers

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are considered insensitive to radiotherapy. However, a growing number of case reports and case series have shown that some lesions treated by radiotherapy achieved an objective response. The aim of the study was to perform a systematic review of all reported cases, case series, and clinical studies of GISTs treated with radiotherapy to reevaluate the role of radiotherapy in GISTs. A systematic search of the English-written literature was conducted using PubMed, Web of Science, and Embase databases. Overall, 41 articles describing 112 patients were retrieved. The included articles were of low to moderate quality. Bone was the most common site treated by radiotherapy, followed by the abdomen. In order to exclude the influence of effective tyrosine kinase inhibitors (TKIs), a subgroup analysis was conducted on whether and which TKIs were concurrently applied with radiotherapy. Results showed that radiotherapy alone or combined with resistant TKIs could help achieve objective response in selected patients with advanced or metastatic GISTs; however, survival benefits were not observed in the included studies. Pain was the most common symptom in symptomatic GISTs, followed by neurological dysfunction and bleeding. The symptom palliation rate was 78.6% after excluding the influence of effective TKIs. The adverse reactions were mainly graded 1–2. Radiotherapy was generally well-tolerated. Overall, radiotherapy may relieve symptoms for GIST patients with advanced or metastatic lesions and even help achieve objective response in selected patients without significantly reducing the quality of life. In addition to bone metastases, fixed abdominal lesions may be treated by radiotherapy. Publication bias and insufficient quality of included studies were the main limitations in this review. Further clinical studies are needed and justified.

show abstract

Section: Patient Response To Radiation and Follow-upmentioning

confidence: 99%

Radiotherapy in the Management of Gastrointestinal Stromal Tumors: A Systematic Review

Zhang

Jiang

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In cases with synchronous unusual site metastases alongside the diagnosis of the primary GIST, the manifestations of the metastatic site are often dominant. For example, when intracranial GIST metastasis occurs, it usually affects the nervous system, resulting in dizziness, headache, memory impairment, loss of sensation and inability to move a single limb, the inability to maintain body balance and abnormal gait and posture, along with a series of neurological crements (27,32,35,40,51,61,70,87,87,92,93). In cases of bone metastasis, pain manifests in the affected bone area (29,37,48,52,53,63,69,75,80,94,95), in cases of skeletal muscle involvement, a mass can be palpated in the affected area (34,49,71,72,79), and when metastasis occurs deep in the bone marrow, anemia may be present (96).…”

Section: Diagnosis Of Rare Site Metastasis Of Gistmentioning

confidence: 99%

“…Treatment and prognosis details described in the literature for rare metastatic sites of GIST are shown in Table II (18,(20)(21)(22)(23)(24)(25)(26)(27)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)43,44,46,47,(50)(51)(52)(53)(54)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)(69)(70)(71)(72)74,75,(77)…”

Section: Therapy and Prognosis For Rare Site Gist Metastasesmentioning

confidence: 99%

“…In addition, radiotherapy may be used as an adjuvant treatment when GIST metastasizes to the skull and bone. At a typical dose of 30 Gy daily, radiation can effectively reduce tumor size and alleviate symptoms, while creating optimal conditions for surgery (40,61,62,78). The administration of 4 mg zoledronic acid intravenously has also been shown to reduce bone destruction in GIST bone metastases (36,75).…”

Section: Therapy and Prognosis For Rare Site Gist Metastasesmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review)

Liang

Kong

2022

Oncol Lett

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GIST) are the most common stromal-derived tumors of the gastrointestinal tract and have a potential metastatic capacity in almost half of all cases, with the most common sites of metastasis being the liver and peritoneum. However, there is evidence that GIST metastasizes to sites other than the liver and peritoneum, which poses challenges for clinical diagnosis and treatment. Therefore, the Cochrane and Medline databases were searched via PubMed in July 2022 using relevant keywords to acquire the literature associated with the metastasis of GIST to rare sites published since from 2000 onwards. Study data comprising age, sex, primary location, metastatic site, mean survival time, clinical signs and symptoms, imaging, pathological features immunohistochemical indices, treatment and prognosis were recorded and analyzed. The 118 metastases at rare sites reported in the literature included bone (n=31), lung (n=10), lymph nodes (n=13), intracranial sites (n=13), skin and subcutaneous tissue (n=10), heart (n=7), skeletal muscle (n=7), orbit and choroid (n=6), pancreas (n=3), spleen (n=2), bone marrow (n=1), testis (n=3), scrotum (n=1), epididymis (n=1), penis (n=1), ovary (n=2), cervix (n=1), kidney (n=1), bladder (n=1), adrenal gland (n=2) and thyroid gland (n=2). From the reviewed studies, it may be concluded that when metastases from gastrointestinal stromal tumors occur at rare sites, the initial symptoms may help in the identification of these sites. In addition, the site-dependent imaging of different metastatic locations may further define the metastases, and the findings of pathological or immunohistochemical analyses may be used to confirm the diagnosis. Contents Introduction 2. Materials and methods3. Rare metastatic sites and basic characteristics of patients 4. Diagnosis of rare site metastasis of GIST 5. Therapy and prognosis for rare site GIST metastases 6.

show abstract

Intracranial metastasis of gastrointestinal stromal tumors: A literature review of published case reports and case presentation

Lee,

Loh,

Yang

et al. 2024

Heliyon

View full text Add to dashboard Cite

Cerebellar metastasis of gastrointestinal stromal tumor: A case report and review of the literature

Cited by 8 publications

References 9 publications

Radiotherapy in the Management of Gastrointestinal Stromal Tumors: A Systematic Review

Radiotherapy in the Management of Gastrointestinal Stromal Tumors: A Systematic Review

Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review)

Intracranial metastasis of gastrointestinal stromal tumors: A literature review of published case reports and case presentation

Contact Info

Product

Resources

About